Littérature scientifique sur le sujet « Plasmacytoid dendritic cell, metastatic melanoma »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Plasmacytoid dendritic cell, metastatic melanoma ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Plasmacytoid dendritic cell, metastatic melanoma"
Monti, Matilde, Raffaella Vescovi, Francesca Consoli, Davide Farina, Daniele Moratto, Alfredo Berruti, Claudia Specchia et William Vermi. « Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis ». Cancers 12, no 8 (28 juillet 2020) : 2085. http://dx.doi.org/10.3390/cancers12082085.
Texte intégralMonti, Matilde, Francesca Consoli, Raffaella Vescovi, Mattia Bugatti et William Vermi. « Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma ». Cells 9, no 2 (11 février 2020) : 417. http://dx.doi.org/10.3390/cells9020417.
Texte intégralGerlini, Gianni, Carmelo Urso, Giulia Mariotti, Paola Di Gennaro, Domenico Palli, Paola Brandani, Adriana Salvadori, Nicola Pimpinelli, Umberto Maria Reali et Lorenzo Borgognoni. « Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes ». Clinical Immunology 125, no 2 (novembre 2007) : 184–93. http://dx.doi.org/10.1016/j.clim.2007.07.018.
Texte intégralPashenkov, Mikhail, Gerda Goëss, Christine Wagner, Markus Hörmann, Tamara Jandl, Anna Moser, Cedrik M. Britten et al. « Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma ». Journal of Clinical Oncology 24, no 36 (20 décembre 2006) : 5716–24. http://dx.doi.org/10.1200/jco.2006.07.9129.
Texte intégralRoyal, Richard Eldon, Luis M. Vence, Tara Wray, Janice N. Cormier, Jeffrey Edwin Lee, Jeffrey E. Gershenwald, Merrick I. Ross et al. « A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. » Journal of Clinical Oncology 35, no 15_suppl (20 mai 2017) : 9582. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9582.
Texte intégralHanks, Brent Allen, Alisha Holtzhausen, Petra Gimpel, Rebekah Jamieson, Olivia M. Campbell, Lihong Sun, Christina K. Augustine et al. « Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment : Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy. » Journal of Clinical Oncology 30, no 15_suppl (20 mai 2012) : 10563. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10563.
Texte intégralWong, Deborah J. L., Aru Panwar, Ari Rosenberg, Vidhya Karivedu, Douglas Earl Laux, Dan Paul Zandberg, Dmitri Bobilev et al. « CMP-001-007 : Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. » Journal of Clinical Oncology 39, no 15_suppl (20 mai 2021) : TPS6089. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps6089.
Texte intégralDavar, Diwakar, Arivarasan Karunamurthy, Douglas Hartman, Richelle DeBlasio, Joe-Marc Chauvin, Quanquan Ding, Ornella Pagliano, Amy Rose, John Kirkwood et Hassane Zarour. « 303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo) : final results ». Journal for ImmunoTherapy of Cancer 8, Suppl 3 (novembre 2020) : A330. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0303.
Texte intégralde Rosa, Francesco, Laura Ridolfi, Laura Fiammenghi, Massimiliano Petrini, Anna M. Granato, Valentina Ancarani, Elena Pancisi et al. « Dendritic cell vaccination for metastatic melanoma ». Melanoma Research 27, no 4 (août 2017) : 351–57. http://dx.doi.org/10.1097/cmr.0000000000000356.
Texte intégralChen, Vivien. « Dendritic-cell vaccination for metastatic melanoma ? » Lancet Oncology 7, no 5 (mai 2006) : 368. http://dx.doi.org/10.1016/s1470-2045(06)70678-7.
Texte intégralThèses sur le sujet "Plasmacytoid dendritic cell, metastatic melanoma"
VESCOVI, Raffaella. « Characterization of plasmacytoid dendritic cells compartment in advanced melanoma ». Doctoral thesis, 2016. http://hdl.handle.net/11562/939213.
Texte intégralPlasmacytoid Dendritic Cells (PDC) are a rare innate immune cells subpopulation .After development, PDC are realised by the bone marrow into the blood stream and migrate from bone marrow to lymph nodes, mucosal associated lymphoid tissue and spleen in steady state conditions. Properly activated PDC may exert antitumor activity through TLR7/9 dependent IFN-α production. IFN-ɑ affects tumor cell proliferation, tumor lymph/angiogenesis, tumor metastasis and enhances the NK cell citoxicity against tumor cells. Autocrine IFNα/β signalling in PDC also modulates a set of interferon-inducible genes such CXCL10/IP-10. IP-10 is a pro-inflammatory chemokine involved in leucocytes recruitment and responsible of Th1 and Th17 polarization of T-cell. PDC recruitment in peripheral tissue has been reported during inflammation and in several types of tumor such as melanoma, head and neck cancer, ovarian carcinoma and breast cancer. Despite of infiltration in many cancers, the PDC anti-tumoral function is still debating. Recent data suggest that PDC could exert a negative regulator role of antitumor response. Emerging hypothesis explains the controversial function of PDC with the tumour microenvironment involvement in subversion of their anti-tumoral activity. Our previous unpublished data on a large cohort of Primary Cutaneous Melanoma (PCM) showed that PDC density within the tumor fails to correlate with a good prognosis in term of IFN-α production. Analysing a cohort of Metastatic Melanoma (MM) patients, we reported a striking decrease of PDC in MM tissues compared to PCM suggesting a severe defect of this population during advanced disease stage. This observation might indicate a reduced PDC bone marrow output or, alternatively, defective migratory properties of PDC. Analysis of Chemokine Receptor (CKR) repertoire of circulating PDC of MM patients suggested lack of activation of these cells. In addition, a significant reduction of circulating PDC and Myeloid Dendritic Cell (MDC) frequencies was detected in blood of MM patients. Interestingly, PDC and MDC reduction was correlated with the tumor burden of MM patients. Moreover, stimulation of TLR7/9 agonists resulted in PDC impairment of MM patients in IFN-α and IP-10 production. Constitutive hyper-activation of the RAF/MEK/ERK pathway is common in melanoma. Combination of BRAF (BRAFi: Vemurafenib and Dabrafenib) and MEK (MEKi: Trametinib and Cometinib) inhibitors represents the standard of care for BRAF mutated MM patients. It is interesting to note that clinical response to Vemurafenib is partially mediated by the immune system. Recently, it has been demonstrated that exposure to MEKi and BRAFi might modulate dendritic cell function. So, we extended the analysis to patients treated with target therapies (i.e. Vemurafenib, Dabrafenib, Trametinib and Cometinib). In our cohort, PDC and MDC frequencies remained unchanged during treatment and single patient analysis revealed no recovery in blood MDC and PDC pool during the treatment. Similarly, PDC capability to produce IFN-α and IP-10 was not restored. This might indicate that microscopic residual disease interferes with PDC function. Alternatively, BRAFi and MEKi might exert some direct effect on PDC function. Our preliminary data obtained on purified PDC suggested that at the therapeutic dose of Vemurafenib cell viability was not affected. Experiments based on an in vitro culture model have enabled us to mimick the direct impact of melanoma cells. PDC viability was affected by melanoma cell supernatant (SN-mel) after 24h of exposure and the death rate was different among different melanoma cell lines. In our experiments, we could observed a downregulation of surface BDCA-2 on PDC after SN-mel exposure. In addition, SN-mel significantly reduced IFN-α and IP-10 production by TLR 7/9 agonists stimulation. These finding suggest that biochemical compounds and ligands produced by melanoma cells affect the survival and function of PDC.
Actes de conférences sur le sujet "Plasmacytoid dendritic cell, metastatic melanoma"
Dillman, Robert O., Andrew N. Cornforth, Carol DePriest, Edward C. McClay, Thomas T. Amatruda, Denysha Carbonell, Cristina DeLeon, Cheryl Mayorga, Robin Ellis et James Cubellis. « Abstract 3703 : Randomized trial of autologous dendritic cell vs tumor cell vaccines in patients with metastatic melanoma ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3703.
Texte intégralCarreno, Beatriz M., Michelle Becker-Hapak, Alexander Huang, Megan Chan, Amer Alyasiry, Wen-Rong Lie, Rebecca L. Aft, Lynn A. Cornelius, Katherine M. Trinkaus et Gerald P. Linette. « Abstract LB-157 : IL-12p70 producing dendritic cell vaccine elicits Tc1 polarized T cells and extends time to progression in metastatic melanoma. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-lb-157.
Texte intégralCornforth, Andrew N., Gary Fogel, Denysha Carbonell et Robert O. Dillman. « Abstract 4845 : Microarray analysis of melanoma autologous tumor cell lines used as the source of tumor associated antigens in patient-specific dendritic cell immunotherapy phase II trial in patients with metastatic melanoma ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4845.
Texte intégralDillman, Robert O., Gabriel I. Nistor, Aleksandra J. Poole et Andrew N. Cornforth. « Abstract 1357 : Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1357.
Texte intégralDillman, Robert O., Gabriel I. Nistor, Aleksandra J. Poole et Andrew N. Cornforth. « Abstract 1357 : Serum levels of programmed cell death molecule-1 (PD-1) as a biomarker in metastatic melanoma patients randomized for treatment with autologous dendritic cell or tumor cell vaccines ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1357.
Texte intégralBritting, Sabine, Niels Schaft, Jan Dörrie, Teresa Bösl, Barbara Bock, Andreas Mackensen et Jacobus J. Bosch. « Abstract 1585 : Primary and metastatic uveal melanoma cell lines express MelanA that can be used as a target antigen for transfection of mature dendritic cells ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1585.
Texte intégralChick, Robert Connor, Annelies T. Hickerson, Guy Travis Clifton, Phillip M. Kemp Bohan, Tommy A. Brown, Jessica L. Cindass, John W. Myers et al. « Abstract 6536 : Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma ». Dans Proceedings : AACR Annual Meeting 2020 ; April 27-28, 2020 and June 22-24, 2020 ; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6536.
Texte intégral